Colorectal Cancer Stage IV Clinical Trial
Official title:
Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
The National Quality Forum has endorsed at least 12 lymph node yield (LNY) as a surgical quality indicator in colorectal cancer (CRC), but the prognostic value of adequate lymphadenectomy has rarely been investigated for CRC patients with distant metastatic disease.
Data on CRC patients with synchronous liver metastasis (LM) were derived from the US Surveillance, Epidemiology, and End Results (SEER) and a Chinese registry (from two Chinese tertiary centers: The Second Affiliated Hospital of Harbin Medical University and National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College) between January 2010 and December 2017. Individual level data on patients with incident CRC were consecutively collected in both registries. The primary tumor site was divided into three subsites according to International Classification of Diseases for Oncology (ICD-O-3) topography codes: proximal colon (C18.0, C18.1, C18.2, C18.3 and C18.4), distal colon (C18.5, C18.6, C18.7) and rectum (C19.9 and C20.9). The synchronous LM were identified by imaging or histopathological examinations. Synchronous LM refers to liver lesions found within 6 months after the diagnosis of primary CRC. Patients were excluded if they did not undergo surgery for CRC, did not have data on number of LNs retrieved and their survival status was unknown. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03594448 -
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
|
||
| Active, not recruiting |
NCT03986541 -
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
|
||
| Completed |
NCT01570452 -
Matrilysin Expression in Different Stages of Colorectal Tumors
|
N/A | |
| Recruiting |
NCT05354817 -
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
|
Phase 2 | |
| Recruiting |
NCT05576896 -
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
|
Phase 2 | |
| Completed |
NCT04715061 -
Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments
|
N/A | |
| Terminated |
NCT03149679 -
The p53 Colorectal Cancer Trial
|
Phase 2 | |
| Enrolling by invitation |
NCT04149613 -
Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
|
||
| Completed |
NCT04425239 -
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT06329700 -
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
|
||
| Recruiting |
NCT05382741 -
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
|
Phase 2 | |
| Recruiting |
NCT06342440 -
Early Detection of Advanced Adenomas and Colorectal Cancer
|
||
| Not yet recruiting |
NCT04917276 -
Treatment Response Prediction System of mCRC Patients Based on CTC
|
||
| Not yet recruiting |
NCT06296056 -
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care
|
Phase 1 | |
| Recruiting |
NCT04714814 -
Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
|
||
| Not yet recruiting |
NCT05451719 -
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
|
Phase 2 | |
| Completed |
NCT03031444 -
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
|
Phase 2/Phase 3 | |
| Completed |
NCT05164419 -
Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
|
||
| Recruiting |
NCT05171660 -
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
|
Phase 3 | |
| Recruiting |
NCT05426005 -
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
|
Phase 1/Phase 2 |